OrbiMed, J&J back $24M A round for microbiome startup; Sangamo, Pfizer win FDA fast track
→ A new microbiome startup, Israel’s BiomX, has raised $24 million in a Series A — OrbiMed, Johnson & Johnson Innovation and Takeda Ventures were in on the round, with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors. BiomX is a preclinical biotech setting the stage for its first human study in the field of gut biology, which has attracted a number of new players over the past few years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.